Quoin Pharmaceuticals, Ltd.
QNRX
$19.00
-$0.17-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.05% | 12.45% | 0.64% | -3.64% | 5.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.02% | 77.49% | 60.97% | 8.45% | 18.95% |
| Operating Income | -59.02% | -77.49% | -60.97% | -8.45% | -18.95% |
| Income Before Tax | -68.02% | -87.23% | -63.80% | -12.75% | -21.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.02% | -87.23% | -63.80% | -12.75% | -21.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.02% | -87.23% | -63.80% | -12.75% | -21.97% |
| EBIT | -59.02% | -77.49% | -60.97% | -8.45% | -18.95% |
| EBITDA | -59.60% | -78.41% | -61.60% | -8.58% | -19.24% |
| EPS Basic | 58.79% | 54.07% | 83.21% | 82.98% | 76.16% |
| Normalized Basic EPS | 58.79% | 54.07% | 83.21% | 82.98% | 76.16% |
| EPS Diluted | 59.15% | 53.95% | 83.21% | 82.92% | 75.92% |
| Normalized Diluted EPS | 58.79% | 54.07% | 83.21% | 82.98% | 76.16% |
| Average Basic Shares Outstanding | 307.62% | 307.62% | 875.54% | 562.77% | 411.70% |
| Average Diluted Shares Outstanding | 309.76% | 309.76% | 882.35% | 562.50% | 412.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |